Michael McClung
Overview
Explore the profile of Michael McClung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1493
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawson-Hughes B, Cosman F, McClung M
J Bone Miner Res
. 2024 Jul;
39(9):1371-1372.
PMID: 39039975
No abstract available.
2.
Yildiz B, Boguszewski C, Boguszewski M, Busetto L, Celik O, Fuleihan G, et al.
Hormones (Athens)
. 2024 Apr;
23(2):183-204.
PMID: 38619812
EndoBridge 2023 took place on October 20-22, 2023, in Antalya, Turkey. Accredited by the European Council, the 3-day scientific program of the 11 Annual Meeting of EndoBridge included state-of-the-art lectures...
3.
Cappola A, Auchus R, Fuleihan G, Handelsman D, Kalyani R, McClung M, et al.
J Clin Endocrinol Metab
. 2023 Jun;
108(8):1835-1874.
PMID: 37326526
Multiple changes occur across various endocrine systems as an individual ages. The understanding of the factors that cause age-related changes and how they should be managed clinically is evolving. This...
4.
Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M
Osteoporos Int
. 2023 Mar;
34(6):1075-1084.
PMID: 36862192
Purpose: To investigate the long-term effect of denosumab on bone microarchitecture assessed by tissue thickness-adjusted trabecular bone score (TBS) in post-hoc subgroup analysis of FREEDOM and open-label extension (OLE). Methods:...
5.
Hans D, Shevroja E, McDermott M, Huang S, Kim M, McClung M
Osteoporos Int
. 2022 Sep;
33(12):2517-2525.
PMID: 36115888
Introduction: To evaluate the effect of denosumab on bone microarchitecture assessed by trabecular bone score (TBS) in the FREEDOM study using the updated algorithm that accounts for regional soft tissue...
6.
Greenspan S, Fitzpatrick L, Mitlak B, Wang Y, Harvey N, Deal C, et al.
Menopause
. 2020 Jul;
27(10):1137-1142.
PMID: 32665529
Objective: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased...
7.
Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A, et al.
Endocr Pract
. 2020 May;
26(5):564-570.
PMID: 32427525
The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with...
8.
Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A, et al.
Endocr Pract
. 2020 May;
26(Suppl 1):1-46.
PMID: 32427503
The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with...
9.
Kendler D, Chines A, Clark P, Ebeling P, McClung M, Rhee Y, et al.
J Clin Endocrinol Metab
. 2019 Oct;
105(3).
PMID: 31665314
Context: There are few studies on patients transitioning from denosumab to bisphosphonates. Objective: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate....
10.
Goodwill A, Campbell S, Henderson V, Gorelik A, Dennerstein L, McClung M, et al.
Neuropsychology
. 2019 Mar;
33(4):581-595.
PMID: 30829514
Objective: Robust norms for neuropsychological tests may offer superior clinical utility to conventional norms, in their ability to distinguish normal cognitive aging from prodromal dementia. However, the availability of robust...